测量青光眼进展的结构与功能软件程序观察者内和观察者间一致性
5名青光眼专家独立评估100例患者的视野进展软件与OCT进展软件打印页,分类为无进展、可疑进展或进展,1个月后重复评估。视野软件观察者内总体κ为0.59-0.87,OCT软件为0.59-0.85;观察者间视野软件κ为0.48(95%CI 0.41-0.55),OCT软件为0.52(95%CI 0.44-0.59)。对进展或治疗改变的判断一致性仅为一般(κ均为0.39),作者认为单独使用这些软件不足以做出决策。
要点
- 视野与OCT进展软件的观察者内一致性为中等至几乎完全(κ 0.59-0.87)。
- 5名专家间观察者间一致性为中等(视野κ 0.48,OCT κ 0.52)。
- 对进展或治疗改变的判断一致性仅为一般(κ均为0.39)。
核心结论
- 青光眼专家使用两种青光眼进展软件包的观察者内一致性为中等,观察者间一致性为中等。
- 这些数据提示,除无进展的患者外,两种设备上的青光眼进展软件包均不足以获得高观察者间一致性。
- 关于进展或治疗改变的低一致性提示,单独使用两种软件均不足以进行决策。
研究设计与样本
- 研究纳入100例患者的视野进展软件和OCT进展软件打印页,随机化后由5名青光眼专家独立进行主观评估。
- 每张图像分类为无进展、可疑进展或进展。
- 主要研究者预先将患者分类为无变异(正常)或测试间高变异(困难)。
- 专家同时评估青光眼损伤是否进展以及是否需要改变治疗。
- 1个月后,同一观察者以不同顺序重新评估患者以确定观察者内可重复性。
主要发现
- 100例观察患者中一半为男性,全部为白人,平均(SD)年龄为69.7(14.1)岁。
- 视野软件观察者内一致性为中等至几乎完全(总体κ[95%CI],0.59[0.46-0.72]至0.87[0.79-0.96])。
- OCT软件观察者内一致性与视野软件相似(总体κ[95%CI],0.59[0.46-0.71]至0.85[0.76-0.94])。
- 5名青光眼专家间视野进展软件观察者间一致性为中等(κ,0.48;95%CI,0.41-0.55),与OCT进展软件相似(κ,0.52;95%CI,0.44-0.59)。
- 观察者间一致性在分类为无进展的图像中为中等,但在分类为可疑青光眼进展或青光眼进展的图像中仅为一般;关于青光眼进展问题(κ,0.39;95%CI,0.32-0.48)和治疗改变考虑(κ,0.39;95%CI,0.32-0.48)的观察者间一致性为一般。
关键数值与推荐
- 视野软件观察者内总体κ[95%CI]范围为0.59[0.46-0.72]至0.87[0.79-0.96]。
- OCT软件观察者内总体κ[95%CI]范围为0.59[0.46-0.71]至0.85[0.76-0.94]。
- 视野进展软件观察者间κ为0.48(95%CI,0.41-0.55)。
- OCT进展软件观察者间κ为0.52(95%CI,0.44-0.59)。
- 关于青光眼进展问题和治疗改变考虑的观察者间κ均为0.39(95%CI,0.32-0.48)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is important to evaluate intraobserver and interobserver agreement using visual field (VF) testing and optical coherence tomography (OCT) software in order to understand whether the use of this software is sufficient to detect glaucoma progression and to make decisions regarding its treatment. OBJECTIVE: To evaluate agreement in VF and OCT software among 5 glaucoma specialists. DESIGN, SETTING AND PARTICIPANTS: The printout pages from VF progression software and OCT progression software from 100 patients were randomized, and the 5 glaucoma specialists subjectively and independently evaluated them for glaucoma. Each image was classified as having no progression, questionable progression, or progression. The principal investigator classified the patients previously as without variability (normal) or with high variability among tests (difficult). Using both software, the specialists also evaluated whether the glaucoma damage had progressed and if treatment change was needed. One month later, the same observers reevaluated the patients in a different order to determine intraobserver reproducibility. MAIN OUTCOMES AND MEASURES: Intraobserver and interobserver agreement was estimated using κ statistics and Gwet second-order agreement coefficient. The agreement was compared with other factors. RESULTS: Of the 100 observed patients, half were male and all were white; the mean (SD) age was 69.7 (14.1) years. Intraobserver agreement was substantial to almost perfect for VF software (overall κ [95% CI], 0.59 [0.46-0.72] to 0.87 [0.79-0.96]) and similar for OCT software (overall κ [95% CI], 0.59 [0.46-0.71] to 0.85 [0.76-0.94]). Interobserver agreement among the 5 glaucoma specialists with the VF progression software was moderate (κ, 0.48; 95% CI, 0.41-0.55) and similar to OCT progression software (κ, 0.52; 95% CI, 0.44-0.59). Interobserver agreement was substantial in images classified as having no progression but only fair in those classified as having questionable glaucoma progression or glaucoma progression. Interobserver agreement was fair regarding questions about glaucoma progression (κ, 0.39; 95% CI, 0.32-0.48) and consideration about treatment changes (κ, 0.39; 95% CI, 0.32-0.48). The factors associated with agreement were the glaucoma stage and case difficulty. CONCLUSIONS AND RELEVANCE: There was substantial intraobserver agreement but moderate interobserver agreement among glaucoma specialists using 2 glaucoma progression software packages. These data suggest that these glaucoma progression software packages are insufficient to obtain high interobserver agreement in both devices except in patients with no progression. The low agreement regarding progression or treatment changes suggests that both software programs used in isolation are insufficient for decision making.
引用
- Moreno-Montañés J, Antón V, Antón A, et al. Intraobserver and Interobserver Agreement of Structural and Functional Software Programs for Measuring Glaucoma Progression. JAMA Ophthalmol. 2017. PMID: 28241171. doi:10.1001/jamaophthalmol.2017.0017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。